What the study found
The authors argue that the approval of zuranolone for postpartum depression and the denial of approval for major depressive disorder can be seen as a case study in recent drug regulation. They also say the approval process was unusually fast because the drug received priority review and fast-track designation.
Why the authors say this matters
The authors suggest that policy changes meant to improve innovation and efficiency may have lowered the evidence threshold for drug approval. They conclude that this may shift the balance of benefits and harms for newly approved medicines in ways that are not in the public’s best interest.
What the researchers tested
The researchers examined the clinical trial data submitted by the manufacturer for zuranolone. They also discussed the drug’s review under U.S. Food and Drug Administration processes, including priority review and fast-track designation.
What worked and what didn't
The abstract states that zuranolone was approved for postpartum depression in August 2023 after a 7-month review. It also states that approval for major depressive disorder was denied. The authors say the designation allowed submission of fewer trials and evaluation based on surrogate outcomes rather than clinically relevant outcomes.
What to keep in mind
The abstract provides the authors’ interpretation, but it does not give the full trial results in the summary available here. It also does not describe detailed limitations beyond noting concerns about the evidence standard used in the approval process.
Key points
- Zuranolone was approved by the U.S. Food and Drug Administration for postpartum depression in August 2023.
- Approval for major depressive disorder was denied.
- The review took 7 months because the drug received priority review and fast-track designation.
- The authors say fast-track designation can allow fewer trials and reliance on surrogate outcomes.
- The paper frames zuranolone’s approval as a case study in recent drug regulatory science.
Disclosure
- Research title:
- Zuranolone approval is presented as a regulatory case study
- Authors:
- Lisa Cosgrove, Milutin Kostić, Barbara Mintzes, Gianna D'Ambrozio, Allen F. Shaughnessy
- Institutions:
- Cambridge Health Alliance, The University of Sydney, University of Belgrade, University of Massachusetts Boston, University of Massachusetts Boston
- Publication date:
- 2026-02-04
- DOI:
- 10.1002/bcp.70472
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with scholarly research without reading academic papers — one filtered digest, every Friday.